Serotype distribution, antimicrobial resistance and prevalence of pilus islets in pneumococci following the use of conjugate vaccines

Journal of Medical Microbiology
Mitsuyo KawaguchiyaNobumichi Kobayashi

Abstract

In Japan, the 7-valent pneumococcal vaccine (PCV7) was introduced in 2010 and, in 2013, the PCV7 was replaced with the 13-valent pneumococcal vaccine (PCV13). This study was conducted to investigate serotypes, antimicrobial resistance and prevalence of pilus islets in pneumococcal isolates from inpatients in a Japanese tertiary hospital. From April 2011 to February 2016, 151 isolates [95 (18 children, 77 adults) and 56 (19 children, 37 adults) in the PCV7 and PCV13 periods, respectively] were collected. All isolates were serotyped using genetic methods and were tested for susceptibility to 18 antimicrobials. Unaltered penicillin-binding protein (PBP) genes, macrolide resistance genes and pilus islets were identified by PCR. Between the two periods, the prevalence of non-PCV13 serotypes was shown to increase from 50.0 to 78.9 % in children, and serotype 3 increased from 14.3 to 24.3 % in adults. Six of seven isolates from invasive diseases were assigned to non-PCV13 serotypes. Overall, multidrug resistance (MDR) was detected in 46.4 % of isolates, which included the dominant non-PCV13 serotypes 6E, 15A and 23A (prevalence≥75.0 %). gPRSP (three altered genes pbp1a, pbp2b and pbp2x) and macrolide resistance genes [erm(B) and/or me...Continue Reading

References

Mar 29, 2005·Antimicrobial Agents and Chemotherapy·Corné H W Klaassen, Johan W Mouton
Feb 17, 2006·Proceedings of the National Academy of Sciences of the United States of America·M A BarocchiB Henriques-Normark
Mar 15, 2006·PLoS Genetics·Stephen D BentleyBrian G Spratt
Feb 14, 2008·The Journal of Infectious Diseases·Monica MoschioniMichèle A Barocchi
May 29, 2010·Emerging Infectious Diseases·Dorothea ZähnerDavid S Stephens
Jun 15, 2013·Emerging Infectious Diseases·Sandra S RichterGary V Doern
Aug 24, 2013·The Journal of Antimicrobial Chemotherapy·Aleksandra K WierzbowskiUNKNOWN Canadian Antimicrobial Resistance Alliance
Jun 25, 2014·Emerging Infectious Diseases·Naoko ChibaUNKNOWN Invasive Pneumococcal Diseases Surveillance Study Group
Sep 16, 2014·Analytical Chemistry·Kamonnaree ChotinantakulAlbert Schulte
Nov 2, 2014·Microbial Drug Resistance : MDR : Mechanisms, Epidemiology, and Disease·Mitsuyo KawaguchiyaNobumichi Kobayashi
May 15, 2015·Journal of Clinical Microbiology·Andries J van TonderAngela B Brueggemann
Oct 9, 2015·Drug Safety : an International Journal of Medical Toxicology and Drug Experience·Emanuel RaschiFabrizio De Ponti
Oct 21, 2015·Emerging Infectious Diseases·Kimiko UbukataUNKNOWN Invasive Pneumococcal Diseases Surveillance Study Group
May 3, 2016·Vaccine·Gili Regev-YochayUNKNOWN PICR study group
Jun 7, 2016·Vaccine·Kate Ching Ching ChanMargaret Ip

❮ Previous
Next ❯

Citations

Oct 13, 2017·Expert Opinion on Biological Therapy·Nicola Principi, Susanna Esposito
Jul 3, 2021·Human Vaccines & Immunotherapeutics·Kenichi TakeshitaNaoki Shimojo

❮ Previous
Next ❯

Related Concepts

Related Feeds

Bacterial Pneumonia (ASM)

Bacterial pneumonia is a prevalent and costly infection that is a significant cause of morbidity and mortality in patients of all ages. Here is the latest research.

Bacterial Pneumonia

Bacterial pneumonia is a prevalent and costly infection that is a significant cause of morbidity and mortality in patients of all ages. Here is the latest research.